Paliroden
Paliroden ( ; developmental code names SR-57667 and SR-57667B) is a drug which was under development for the treatment of Alzheimer's disease and Parkinson's disease but was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Paliroden ( ; developmental code names SR-57667 and SR-57667B) is a drug which was under development for the treatment of Alzheimer's disease and Parkinson's disease but was never marketed. It is taken orally. The exact mechanism of action of the drug does not appear to have been disclosed, but it has been found to stimulate neurogenesis in preclinical research.
It was under development by sanofi-aventis. Paliroden reached phase 2 clinical trials for Alzheimer's disease and Parkinson's disease prior to the discontinuation of its development in 2007.
It is an analogue and follow-on drug of xaliproden (SR-57746; SR-57746A), which is a serotonin 5-HT 1A receptor agonist and neurogenesis stimulant that reached phase 3 trials for similar indications but also did not complete development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370487720 under CC BY-SA 4.0; modifications have been made.